Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00084253|
Recruitment Status : Completed
First Posted : June 11, 2004
Last Update Posted : March 5, 2010
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Atazanavir/ Stavidine / Lamivudine Drug: Atazanavir-Ritonavir/ Stavidine / Lamivudine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase IV Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients|
|Study Start Date :||June 2004|
|Actual Primary Completion Date :||August 2006|
|Active Comparator: 1||
Drug: Atazanavir/ Stavidine / Lamivudine
Capsules, Oral, ATV (2 x 200 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD, Once daily, 96 weeks.
Other Name: Reyataz
|Active Comparator: 2||
Drug: Atazanavir-Ritonavir/ Stavidine / Lamivudine
Capsules, Oral, ATV (2 x 150 mg) QD + RTV (1 x 100 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD*, Once daily, 96 weeks.
Other Name: Reyataz
- To compare the proportion of subjects responding to treatment with HIV RNA levels < LOQ (400 c/mL) through Week 48 in treatment naive subjects for ATV and ATV/RTV (each combined with 3TC and d4T XR).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00084253
|United States, New Jersey|
|Various locations within the US|
|Call for Information, New Jersey, United States|
|Study Director:||Bristol-Myers Squibb||Bristol-Myers Squibb|